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Ocular allergy is one of the most common disorders of the eye surface. Following diagnosis this 
condition is typically treated with preparations containing antihistamines. However, anatomy of the 
eye and its natural protective mechanisms create challenges for ocular drug delivery. Rapid elimination 
of antihistamine substances due to short residency times following application can lead to insufficient 
treatment of ocular allergies. With this in mind, the aim of this study was to prepare a controlled ocular 
delivery system to extend the retention time of olopatadine hydrochloride (OLO) and in doing so to 
reduce the need for frequent application. We developed extended-release ocular in situ gelling systems 
for which in vivo retention times were determined in sheep following in vitro characterization and 
cytotoxicity studies. In vivo results were then compared to commercially available Patanol eye drops. the 
transparent gels formulated using appropriate amounts of polymers and having longer ocular retention 
times appear to be a viable alternative to commercially available eye drops. 
Keywords: Olopatadine hydrochloride. Ocular allergy. In situ gelling system. 
INTRODUCTION
Generally, there are two main purposes of ocular 
drug applications: treating ocular diseases emerging on 
the surface (conjunctivitis, keratitis, etc.) and treating 
those emerging in deeper layers (glaucoma, uveitis, 
etc.). The most common commercial dosage form for 
ocular administration is the eye drop which makes up 
approximately 90% of the formulations on the market 
(Bourlais et al., 1998; Bain et al., 2009; Vadlapudi et al., 
2015; Mehanna, El-Kader, Samaha, 2017). 
Ocular  al lergies include  seasonal  al lergic 
conjunctivitis, hay fever, vernal keratoconjunctivitis, 
chronic allergic conjunctivitis, and atopic conjunctivitis. 
Furthermore, contact lens-induced papillary conjunctivitis 
and papillary conjunctivitis which develops after surgery 
are also included within the scope of ocular allergies. 
Seasonal allergic conjunctivitis, which is the most 
common form of ocular allergy, is a condition caused by 
a sudden reaction to substances like pollen, animal hair, 
dust, or chemicals. (Palmer, 2007). The most important 
symptom of ocular allergy is itchiness. Swelling on the 
conjunctiva can also occur. Palpebrae may become tumid 
and a change can occur within the structure of tender 
collagen fibers around the eye depending on the degree 
of swelling (Barney, Cook, Stahl, 2014). 
O l o p a t a d i n e  h y d r o c h l o r i d e  ( 11 - [ ( Z ) - 3 -
(dimethylamino)propylidene]-6,11-dihydrodibenz [b, 
e] oxepin-2-acetic acid hydrochloride, OLO) is a white, 
crystalline, water-soluble compound with a molecular 
weight of 373.88 (Ohmori et al., 2002; Leonardi, Quintieri, 
2010). OLO is an anti-allergic active pharmaceutical 
ingredient with histamine H1 receptor antagonistic action 
which also has an effect on human conjunctival mast cells. 
The compound is capable of suppressing the mast cell 
concentration at least ten times more than its clinically 
effective concentration (Brockman et al., 2003; Tamura, 
Komai, 2008). Due to its antihistaminic feature and effect 
on mast cells, treatment begins rapidly and long-term 
protection is provided (Abelson, Spitalny, 1998). 
Although topical application offers many advantages 
for the treatment of ocular surface disorders, it can result 
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in severe bioavailability issues due to various biological 
factors involved in the process of eye protection (Kaur 
et al., 2004). Many commercial drug companies suggest 
50 µL as the maximum volume for eye drop application; 
however, only about 30 µL remains on the eye surface. 
Therefore, active pharmaceutical ingredient is wasted 
because of the excessive application volume required 
(Kaur et al., 2004; Rawas-Qalaji, Williams, 2012). 
Following ocular application, pre-corneal factors 
and anatomic hindrance have a negative effect on the 
bioavailability of topical formulations. Pre-corneal factors 
include solution drainage, loss due to blinking, formation 
of tear film, and increase in tear secretion. Tears secreted 
from the lacrimal glands at the corner of the eye orbit are 
a mixture of antimicrobial enzymes, lysozyme, salts, and 
mucus. Formation of a tear film indicating the presence 
of a healthy eye surface is the first step in providing 
high resistance. This film cleans the pathogens on the 
ocular surface and plays a protective role by forming a 
hydrophilic surface. Considering all of the pre-corneal 
factors, actual contact time of an applied ocular dose was 
determined to be low and < 5% actually was instilled into 
the intraocular tissues (Başaran et al., 2010; Perrie et al., 
2012; Morrison, Khutoryanskly, 2014). Based on these 
facts as well as other issues, new drug delivery systems 
providing continuous and controlled release such as 
in situ gel, nanoparticles, microemulsions, liposomes, 
nanosuspensions and ocular inserts have emerged in recent 
years (Tangri, Khurana, 2011).
There has been a growing interest in ocular in situ 
gelling systems which undergo physical or chemical 
changes in their structure and transform into a gel form. 
This phenomenon has been used by many researchers to 
increase the retention time of drugs on the ocular surface to 
provide sustained release, to increase stability of protein-
based drugs, and to formulate active drug delivery systems 
when required (Thrimawithana et al., 2012; Patil, Kumar, 
2015). 
In situ gel is generally expressed as a polymer 
solution in liquid form when applied which is converted 
into a semi-solid gel phase when exposed to physiologic 
conditions. Gelling can be achieved by ultraviolet 
application or with solvent exchange depending on 
temperature, pH, and ion change (Rathore, 2010).
Triblock copolymers of polyethylene glycol-
b-polypropylene and glycol-b-polyethylene glycol, 
commercially available as Pluronic, are non-ionic, water-
soluble materials of great interest as pharmaceutical 
excipients. These polymers have an amphiphilic 
character, surfactant property and may interact with 
hydrophobic surfaces and biological membranes. 
Pluronic is a polymer which undergoes a gelation process 
depending on elevation of temperature. It can be used 
frequently in ophthalmology due to its transparent 
structure and the fact that it causes no disturbance in 
vision after application (Batrakova, Kabanov, 2008; 
Khateba et al., 2016).
Poloxamer, belonging to the same group as Pluronic, 
is a biocompatible polymer commonly used for medicinal 
and pharmaceutical purposes. Various potential uses 
for Poloxamer in oral preparations are being examined 
in addition to ocular, nasal, topical, rectal, vaginal, and 
intrauterine applications.
To overcome the short residence time and to reduce 
the application frequency of conventional ocular delivery 
systems containing an antihistaminic substance, an OLO 
sustained-release drug delivery system was designed 
to treat ocular allergies (Paavola, Bernards, Rosenberg, 
2016).
MATERIAL AND METHODS 
Material
Poloxamer (Sigma, code: 16758), Pluronic F 127 
(Sigma, code: P2443) and hydroxypropyl methylcellulose 
(HPMC, Sigma code: H7509) used as polymers for in situ 
gel formulations were purchased from Sigma-Aldrich 
(Germany), sodium chloride (NaCl) used for isotonic 
adjustment from Merck (Germany), benzalkonium 
chloride used as preservative from Fluka, and distilled 
water from Millipore. 
Simulated tear fluid (STF) consisted of 0.680 g NaCl 
(Merck), 0.220 g NaHCO3 (Sigma-Aldrich, code: S6014), 
0.008 g CaCl2⋅2H2O (Sigma-Aldrich, code: 449709), 
0.14 g KCl (Merck), and distilled water to 100 mL. 
Preparation of in situ gel systems
Two methods, namely the ‘hot method’ and ‘cold 
method’, were used to prepare the gel systems. Polymeric 
solutions were prepared using the cold method (Li et 
al., 2015). Briefly, the required quantity of polymer was 
dispersed in cold water with continuous magnetic stirring 
at 4 ºC for at least 24 hours. Formulation studies were 
started by determining constituent ratios. For polymers 
in different percentages, proportions were selected in 
parallel with that reported in the literature (Rawat, Warade, 
Lahoti, 2010). The amount of NaCl for formulations was 
calculated according to Raoult’s law to obtain isotonic 
aqueous solutions. The concentration of the preservative 
was 0.01% benzalkonium chloride in accordance with the 
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most commonly used ophthalmic ingredient on the market. 
Compositions of the in situ gel formulations prepared are 
detailed in Table I. 
Measurement of sol-gel transition (gelation 
temperature)
The most ideal ophthalmic in situ gel formulation is 
one that transitions at 32°C which is the temperature of the 
ocular surface. Tsol-gel of formulations vary depending 
on the amount of polymer. Therefore, to determining the 
gelation temperature of each formulation prepared, the Test 
Tube Tilting Method from 0 °C to 50 °C was employed 
(Bain et al., 2009). The study proceeded with those gelling 
systems undergoing transition at appropriate temperatures. 
Briefly, a 2 mL aliquot of prepared solution was transferred 
to a 5 mL test tube in a water bath maintained at 0 °C. 
The temperature of the bath was incrementally increased 
to 50 °C. At every temperature point the solution was 
permitted to equilibrate for 1 min. The samples were 
checked for gelation by tilting the test tube at 90°. The 
solutions were said to gel when no mobility was observed. 
Measurements were made in triplicate and the mean value 
calculated. 
U-HPLC analysis of OLO
Samples were analyzed using a U-HPLC system 
(Agilent Technology 1290 Infinity, USA) installed with 
Zorbax Eclipse Plus C18 (2.1x50 mm 1.8 Micron). The 
column compartment was temperature-controlled and a 
PDA detector was employed throughout the analysis. 
A new U-HPLC method was developed for OLO. 
Methanol-distilled water-sodium acetate buffer (40:50:10 
v/v/v) was determined to be the mobile phase after testing 
different ratios and phases at a flow rate of 1 mL/min. The 
column oven was set at 40°C. Sodium acetate buffer 0.1 M 
prepared using acetic acid was adjusted to pH 4.5. The 
U-HPLC method was validated with respect to system 
suitability, linearity, precision, accuracy/specificity, 
selectivity, limit of detection (LOD), quantitation (LOQ), 
and stability (ICH, 2005). 
Characterization of in situ gelling system
Physical appearance and clarity
In situ gel formulations prepared containing the 
active ingredient were visually examined for physical 
appearance. The clarity of gelling systems was assessed 
TABLE I - Composition percentage of in situ gel formulations
Code
Polymers
Olopatadine 
Hydrochloride
NaCl
Benzalkonium 
Chloride
water
Poloxamer®
Pluronic® F 
127 HPMC
P10 10 - - 0.1 0.884 0.01 qs 100
P12 12 - - 0.1 0.884 0.01 qs 100
P14 14 - - 0.1 0.884 0.01 qs 100
P16 16 - - 0.1 0.884 0.01 qs 100
P18 18 - - 0.1 0.884 0.01 qs 100
P20 20 - - 0.1 0.884 0.01 qs 100
F10 - 10 - 0.1 0.884 0.01 qs 100
F12 - 12 - 0.1 0.884 0.01 qs 100
F14 - 14 - 0.1 0.884 0.01 qs 100
F16 - 16 - 0.1 0.884 0.01 qs 100
F18 - 18 - 0.1 0.884 0.01 qs 100
F20 - 20 - 0.1 0.884 0.01 qs 100
FH1205 - 12 0.5 0.1 0.884 0.01 qs 100
FH121 - 12 1 0.1 0.884 0.01 qs 100
FH1405 - 14 0.5 0.1 0.884 0.01 qs 100
FH141 - 14 1 0.1 0.884 0.01 qs 100
FH1605 - 16 0.5 0.1 0.884 0.01 qs 100
FH161 - 16 1 0.1 0.884 0.01 qs 100
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using white and black backgrounds to avoid overlooking 
particulate matter. 
pH analysis
The pH values of freshly prepared dispersions were 
determined at 25±1 °C by WTW Profi Lab (pH 597, 
Weilheim, Germany). All analyses were repeated in 
triplicate.
Gelling capacity
A drop of the formulation was placed into 2 mL of 
freshly prepared STF and the gelling time was visually 
recorded to determine gelling capacity of the formulations 
prepared using active substances. The code system 
specified in Table II was used to rate the gelling capacities 
(Rathore, 2010; Morsi et al., 2016). 
Swelling study
STF was used at a temperature of 32±1 °C for 
formulation swelling studies. A volume of 1 mL of the 
formulations was placed on a dialysis membrane and 
sealed to prevent leakage. Prior to testing (t0), gel weight 
was measured and recorded, after which the gel was kept 
in STF for specified times (0.5, 1, 2, 3, 6, 12, 24 hours). 
Swelling rates were calculated using the following 
formula: (Bhowmik et al., 2013).
Swelling ratio (t) % = {(gel weight (t) - gel weight (t0)) / 
gel weight (t0)} x 100
Examination of rheological behavior and viscosity
Rheological properties were determined using a 
cone-and-plate geometry rheometer with a diameter of 
40 mm (Brookfield, USA). Measurements and viscosity 
changes were repeated at two different temperatures, 
25±1 °C and 32±1 °C. Shear rates against shear stress 
were calculated to provide further information regarding 
flow properties. 
In vitro drug release study
STF was used as the release medium for obtaining 
in vitro release profiles of freshly prepared formulations 
(Başaran et al., 2010). Release studies were performed 
using the dialysis membrane method with magnetic 
stirring at a speed of 100 rpm and at an ocular surface 
temperature of 32±1 °C (Sniegowski et al., 2015). 
Release tests were repeated 3 times for each formulation. 
Quantification of the active ingredient, OLO, was achieved 
using the pre-validated U-HPLC method. Release medium 
with a total volume of 40 mL was adjusted to obtain sink 
conditions. The 1 mL of STF sample withdrawn each time 
was replaced with a fresh sample. 
Cytotoxic evaluation
The MTT method was used to investigate the 
cytotoxic effect of various OLO-containing formulations 
on cells in comparison to Patanol, the only commercial 
product containing OLO. Mouse NIH 3T3 fibroblasts were 
cultured. Formulations containing 2% OLO were dispersed 
in the medium and applied onto the cells at concentrations 
of 5, 10, 30, 90, 120, 150, and 200 μg/100 μL. At the end 
of 12- and 24-hour incubation periods, absorbance was 
measured at 572 nm using a BioTek Cytation 5 (BioTek 
Instruments, Germany) multiple plate reader. For the 
cytotoxicity tests, 3 plates were used for each formulation 
and 8 wells were used for each concentration. Intact 
cells incubated in the culture medium were used as the 
control group. Results were expressed as the percentage 
of absorbance of control cells. Since no cytotoxicity was 
observed during the first 12 hours of incubation, IC50 
(inhibitor concentration causing 50% decrease in cell 
proliferation) values were determined at the end of the 
24-hour incubation period.
In vivo retention time study
The in vivo experimental protocol was approved 
by the Local Animal Ethical Committee of Osmangazi 
University (Approval No. 518-1). In vivo studies were 
performed at the MD Center Livestock Farm and 
accompanied by a veterinary surgeon. A total of 6 healthy 
female/male Anatolian Merino sheep, 1-2 years old, 
weighing 25-40 kg were used. Within the scope of the 
study, each of the 5 formulations was applied to one eye 
of the 6 sheep once a day without disturbing the animals. 
Following the application, tear samples were collected 
and measured using Schirmer’s tear test at the 30th minute 
and 1st, 2nd, 3rd, 6th, 24th and 48th hours (Figure 1). The test 
membrane was contacted with the eye for 30 seconds at 
each sampling time point. A total of 14 tear samples were 
collected from the sheep, that is, 7 samples from each eye. 
TABLE II - Grading of gelling capacities
- No gelation occurred.
+ The gel formed after a few minutes and dissolved rapidly.
++ The gel formed immediately and remained for a few hours.
+++ The gel formed immediately and remained for an extended 
period of time.
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Sex-related changes were not taken into consideration 
since both female and male sheep were used in each group. 
Samples taken from the test membrane were stored at 
-20°C until analyzed. The amount of OLO in tear samples 
was determined by the U-HPLC method. Data obtained 
indicated retention time of formulations in the eye.
Statistical data analysis
The difference between the test animals and the 
control group was evaluated statistically by applying a 
one-way ANOVA Tukey test. The GraphPad Prism version 
5.0 statistical program was used for the statistical analysis 
of the complete data obtained. The significance level was 
evaluated as 95% (p<0.05).
RESULTS AND DISCUSSION
Preparation of in situ gel systems
The widespread ocular use and non-toxic nature 
of Poloxamer and Pluronic F were advantageous in this 
study. Furthermore, the water-soluble character of HPMC, 
transparency, and proper viscosity of its solution and 
widespread use in ophthalmology supported the preference 
of gel formulations in this study (Khangtragool, 2014). 
Aqueous solutions of different concentrations of 
Poloxamer and Pluronic F were prepared and evaluated for 
gelation temperature to identify the compositions suitable 
for use as in situ gelling systems. 
Measurement of Tsol-gel (gelation temperature)
A perfect thermosensitive ophthalmic gel should 
have a Tsol-gel higher than room temperature, ideally 
30°C, and form a gel at precorneal temperature even 
when diluted by a small volume of tear liquid. If transition 
occurs at temperatures below 30°C, the in situ gel would 
already be gelled when instilled to the eye and if gelation 
happens at higher temperatures, the formulation would be 
drained by lachrymal secretions without filling the need 
(Venkatesh et al., 2011). 
Gelation temperature differs depending on the 
concentration of ingredients in the formulation, particularly 
the polymer. Therefore, formulations to be applied 
ophthalmically should gel at the surface temperature 
of the eye. When the polymer concentration is too low, 
gelation at 32°C will not be achieved and use of polymer 
at very high concentrations increases both the cost and 
the toxic effects. Therefore, determining the minimum 
concentration at which gelation occurs at 32°C is the goal 
(Jeong, Kim, Bae, 2002). In the Test Tube Tilting Method 
used in this study, the temperature is gradually increased 
over time so that the phase transition can be visually 
recorded and the gelation temperature determined. The 
gelation temperatures of the formulations are presented 
in Table III. The Tsol-gel obtained for various Poloxamer 
concentrations (14%-20% w/w) is in accordance with the 
results described in the literature and proves that the Tsol-
gel is dependent on polymer concentration (Gratieri et 
al., 2010). Formulations demonstrating ratios of polymer 
(P16, F16, F1405) which could gel at 32°C were selected 
for in situ preparations.
U-HPLC analysis of OLO
The U-HPLC method used to determine OLO in 
both in vitro and in vivo studies was preferred because of 
its many advantages. This method is very sensitive and the 
detection limits (LOD and LOQ) are rather low. Due to the 
much smaller particle size in U-HPLC columns, it is more 
resistant to pressure and the signals are clearer due to the 
low inter-particle spaces within the column. In addition, 
the analysis period is short enough to be expressed in 
seconds and the volume of the mobile phase is much lower 
(Novakova, Matysova, Solich, 2006). 
As a result of the validation study, the determination 
coefficient (r2) was found to be 0.9997 and linearity, 
accuracy, and precision in the operating range were 
observed to be within acceptable limits. The limit of 
quantification (LOQ) was determined as 2.3188 μg/mL 
and the limit of detection (LOD) was found to be 0.7652 
μg/mL. 
Characterization of in situ gelling system
Physical appearance and clarity
Physical appearance and transparency are the first 
issues investigated when examining physicochemical 
properties of gel systems. In most studies when the 
existence of particles was visually observed under light on 
FIGURE 1 - Sampling with Schirmer tear test membrane.
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a black-and-white background no changes in transparency 
and uniform appearance were observed in the formulations 
prepared (Gupta et al., 2007). 
pH analysis
The pH value should be 7.2±0.2 to ensure maximum 
comfort after application of an ideal ophthalmic 
preparation. However, preparations with different pH 
values can be tolerated due to the buffering capacity of 
tears. Therefore, an ophthalmic preparation with a pH 
value between 4.0 and 8.0 can be applied (Ammar et al., 
2009; Fialho, Silva-Cunda, 2004). 
Average pH value of the in situ gel formulations 
we prepared was between 6.50 and 7.00, which was 
appropriate for ophthalmic application (Table III). 
Fortunately, there was no need for pH adjustment using 
any additional chemicals because substances added to the 
formulation could be detrimental in terms of toxicity or 
stability. In a similar study, it was reported that the average 
pH value of the ophthalmic in situ gel system developed 
was approximately 6.5 and this value was tolerated by the 
eyes (Mandal et al., 2012).
Gelling capacity
Viscosity and gelling capacity are the two essential 
features of in situ gel systems. Formulations with 
appropriate viscosity and gelling can easily be applied 
as eye drops leading to increased patient compliance. 
Gelling capacities of the formulations determined visually 
according to the coding system reported in the literature 
are presented in Table II (Gupta et al., 2007; Rathore, 
2010).
As shown in Table II, formulations containing 20% 
polymer had a grade of “+++” as the gel formed at room 
temperature (< 25ºC) and did not exhibit free-flowing 
properties at 4ºC. However, P16 and F16 achieved a “++” 
grade for gelling capacity as it formed immediately and 
remained for a few hours. The HPMC added formulation, 
FH1405, had a grade of “+++” as the gel formed at 32ºC. 
Formulations containing the lowest polymer content did 
not exhibit gelling capacity as they remained in a solution 
state at both non-physiological (4ºC) and physiological 
(32ºC and over) conditions showing no gelation. 
From these outcomes, it was discovered that the 
thermosensitivity of gel is profoundly concentration 
dependent, with higher concentrations leading to faster 
gelation at lower temperatures (Almeida et al., 2013). 
Swelling study
One of the tests used in considering an in situ gel 
system is the swelling capacity. Transformation of a gel 
system depending on time and temperature are examined 
with a swelling study (Ju et al., 2013). This test also gives 
some ideas as to the cross-linking ratio of gel, diffusion of 
active substance, and its interaction with the tissue (Diniz 
et al., 2015). 
When swelling of in situ gel formulations calculated 
using STF were compared, it was found that the swelling 
of F16 was higher than P16 and FH1405 (Fıgure 2). 
Weight of the gel increased in a rapid pattern until the 
6th hour followed by an increase in a slower pattern. 
Considering the duration of ophthalmic retention, it was 
decided to continue the test up to 24 hours. 
The perfect formulation in solution form ought to 
have an ideal viscosity that will allow for easy installation 
into the eye, and a fast Tsol-gel. In this case, P16 and F16 
gave reliable results and were selected as the optimized 
batches.
Examination of rheological behavior and viscosity
Viscosity of all formulations prepared presented 
linear behavior until 30ºC (Figure 3). Just after 30ºC an 
increase in viscosity was seen which remained constant 
above 35ºC. Constant viscosity above 35°C helps maintains 
longer ophthalmic retention time of formulations. When 
the formulations were tested rheologically at a shear rate 
range of 0-800 sec-1 at 25°C, linear correlation between 
shear rate and shear stress was determined, indicating a 
Newtonian flow type (Figure 4). When solution transforms 
TABLE III - pH, gelling capacity and gelation temperature of 
in situ gelling (n=6)
Code pH (Mean ± SE)
Gelling 
capacity
Gelation 
temperature (°C)
P16 6.61±0.00 ++ 32
F16 6.60±0.00 ++ 32
FH1405 6.70±0.00 +++ 32
FIGURE 2 - Swelling profiles of in situ gel formulations (n=3).
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to a gel at 32°C, shear stress and shear rate conform to the 
pseudoplastic flow model. Thus, temperature dependent 
rheological behavior of all formulations was confirmed by 
the Newtonian flow model at 25ºC and the pseudoplastic 
model at 32ºC (Lin, Sung, Vong, 2004; Chang et al., 2002).
In vitro OLO release study
An in vitro release study was performed for P16, 
F16, and FH1405 in comparison to Patanol. From Figure 
5, it is obvious that OLO in a structured in situ gel system 
resulted in a significant (p < 0.05) slower release of OLO. 
Three different in situ gel system preparations exhibited 
similar release profiles (Figure 5). 
Formulations P16, F16, and FH1405 showed 
60.33%, 61.21%, and 53.73% drug release, respectively 
at the end of 24 h. Initially, release of drug from these 
formulations was higher due to the bursting effect and as 
the time period increased the gelation effect occurred and 
release rate was finally retarded. P16 and F16 formulations 
demonstrated higher release compared to FH1405. This 
difference was attributed to the higher gelation capacity 
and viscosity of the FH1405 formulation compared to 
the other two formulations. The results show that the 
percentage of OLO released from P16 and F16 were 
nonsignificantly (p < 0.05) lower than that released from 
FH1405. This outcome might be due to HPMC, which may 
have played a significant role in retarding the release of the 
drug, probably by slowing down polymer disintegration 
(Morsi et al., 2016). 
OLO in Patanol eye drops was released rapidly 
during the first minute and its concentration exceeded 75% 
at the 6th hour. All the formulations prepared demonstrated 
extended and retarded release characteristics when 
compared to Patanol.
Cytotoxic evaluation
It is important that the formulations developed have 
low body cell toxicity. The MTT test, involving water-
soluble yellow tetrazolium dye reduction by living cells 
to a purple formazan salt insoluble in aqueous solutions, 
was used in this study to determine the cytotoxic potentials 
of all formulations. The amount of formazan produced is 
directly proportional to the amount of living cells which 
can be measured spectrophotometrically (Arranja et al., 
2014; Şenel, Büyükköroğlu, Yazan, 2015).
In this study, concentration dependent cell depletion 
was observed in the first 12 hours with respect to 
formulations prepared using HPMC, with cell viability 
not going below 50% even at the highest dose (Figure 6). 
FIGURE 3 - Effect of temperature on viscosity of formulations 
(n=6).
FIGURE 4 - Effect of temperature on rheological behavior of formulations. (A25 F16, 25 °C; B25 P16, 25 °C; C25 FH1405, 25 °C; 
A32 F16, 32 °C; B32 P16, 32 °C; C32 FH1405, 32 °C).
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However, cell viability was close to 50% at approximately 
30 μg/100 μL at 24 hours. Higher cytotoxicity was 
observed in Pluronic F 127 formulations, whereas 
Poloxamer 407 formulations showed 50% cell viability 
only at the highest dose of 200 μg/100 μL. When we 
evaluated cytotoxicity for Patanol, the cell viability 
decreased to 50% only at the highest dose (200 μg/100 μL) 
during the 12 hour incubation period, while cell viability 
decreased to < 50% at approximately 90 μg/100 μL after 
24 hours of incubation.
It was determined that the formulations prepared 
in this study showed cytotoxicity only at high doses 
depending on concentration and time. While some of the 
results obtained are consistent with those in the literature, 
some are not. These discrepancies may be attributed to 
the sparse number of previous studies and differences in 
concentrations and time values used in those studies. 
In vivo retention time studies
The amount of OLO in tear samples taken from 
the sheep was successfully measured using the validated 
U-HPLC analytical method. Samples collected by soaking 
them on ‘Schirmer’s tear test’ membranes appeared 
to result in enhancement of bioavailability due to the 
prolonged ophthalmic retention time (Byrro et al., 2012; 
Bhatta et al., 2012). 
Redness must be controlled for in eyes that receive 
formulations. From application to final tear sampling 
there was no redness or irritation in the eyes of the sheep 
used in this study. According to our findings, OLO in 
all formulations was determined to be at significant 
ophthalmic concentrations until 6 hours, while no OLO 
was found in the Patanol group in the 2 hour samples. OLO 
detected between 6 and 24 hours was found to be under 
analytically acceptable concentration limits (LOD and 
LOQ); therefore, the concentration could not be calculated 
at 24 hours. 
A statistically significant difference was observed 
between the Patanol group and all formulations (p<0.05). 
It was proved that ophthalmic retention time was much 
longer for in situ gel preparations than solution application. 
Therefore, the frequency of application can be decreased 
and patient compliance increased with the added benefit 
of a reduction in the risk of toxic effects resulting from 
frequent dose repetition. 
CONCLUSION 
The present study showed the development and 
evaluation of OLO-loaded in situ gelling systems. The 
most important parameter for the success of treating 
allergic conjunctivitis, which is an ocular superficial 
disorder, is to ensure that the active substance remains 
on the eye surface for an extended period of time. Rapid 
FIGURE 5 - Cumulative release percentage from gel formulations 
in simulated tear fluid (n=3).
FIGURE 6 - Cell viability of formulations on human 3T3 cells.
FIGURE 7 - Concentration-time profiles of OLO after 
administration of in situ gel formulations and Patanol (n=6).
Development and in vitro/in vivo evaluation of thermo-sensitive in situ gelling systems for ocular allergy
Braz. J. Pharm. Sci. 2019;55:e17511 Page 9 / 11
excretion resulting from drainage following eye drop 
application causes frequent repetition of dosing, which 
may lead to irritation and eye toxicity long-term. The 
in situ gel systems developed in this study provided 
sustained release over an extended period with once-daily 
application. In this study, a thermosensitive in situ gel of 
OLO was prepared which exhibited appropriate gelation 
temperature, quick transition, sufficient viscosity, extended 
drug release, and negligible ocular toxicity. In vivo 
retention time studies showed that commercially available 
Patanol ophthalmic solution was effective for only 2 hours 
while the gel systems developed and tested were still at 
significant ophthalmic OLO concentrations at 6 hours after 
administration. Use of in situ gel systems appears to be 
promising as an alternative to eye drops. Benefits of such 
a system include increased patient compliance as a result 
of the need for less frequent application sufficient to treat 
pharmacologic allergy symptoms.
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